Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Franciscus Dorjee | M | 63 |
University of Amsterdam
| 7 years |
| Mikael Oerum | M | - |
Regenesance BV
 Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | 2 years |
| Richard W. Beentjes | M | 63 |
University of Amsterdam
| 5 years |
| Wim Henk Steenpoorte | M | 60 |
University of Amsterdam
| 6 years |
| Mikael Ørum | M | 71 |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | - |
| Rita de Boer | F | - |
University of Amsterdam
| 6 years |
| Hergen Spits | M | - |
University of Amsterdam
| 4 years |
| Jacob A. Moulijn | M | - |
University of Amsterdam
| 10 years |
| Ben Jansen | M | - |
University of Amsterdam
| 3 years |
| Martin J. Thoolen | M | - |
University of Amsterdam
| 3 years |
| Michiel von Saher | M | - |
University of Amsterdam
| 12 years |
| Leonardus H. T. van der Ploeg | M | 69 |
University of Amsterdam
| 1 years |
| Jef M. van der Zel | M | - |
University of Amsterdam
| 3 years |
| Arjen Hooiveld | M | - |
University of Amsterdam
| 4 years |
| Nanno Wams | M | - |
University of Amsterdam
| 3 years |
| Jan Boekelman | M | - |
University of Amsterdam
| 4 years |
| Valeria Ramaglia | M | - |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | - |
| Albert Gerard Koenders | M | 66 |
University of Amsterdam
| 4 years |
| Thijs Berman | M | 66 |
University of Amsterdam
| 1 years |
| Philip van den Berg | M | 66 |
University of Amsterdam
| 4 years |
| Raoul J Bino | M | - |
University of Amsterdam
| 6 years |
| Robert Hendriks | M | - |
University of Amsterdam
| 3 years |
| Hendrikus van Westendorp | M | 59 |
University of Amsterdam
| 4 years |
| Esther Mot | F | - |
University of Amsterdam
| 7 years |
| Leo de Haan | M | - |
University of Amsterdam
| 1 years |
| Henri Nico Doods | M | - |
University of Amsterdam
| 3 years |
| Titia de Lange | M | - |
University of Amsterdam
| 3 years |
| Annerie Vreugdenhil | F | 60 |
University of Amsterdam
| 3 years |
| Michiel Kruyt | M | - |
University of Amsterdam
| 5 years |
| Johannes van der Salm | M | 60 |
University of Amsterdam
| 4 years |
| Jan Palmen | M | - |
University of Amsterdam
| 2 years |
| Kees Fluiter | M | - |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | - |
| Marnix A. Snijder | M | 78 |
University of Amsterdam
| 3 years |
| Martijn Kleijwegt | M | 69 |
University of Amsterdam
| 4 years |
| Domenico Valerio | M | 67 |
University of Amsterdam
| 1 years |
| Marc W. Staal | M | 64 |
University of Amsterdam
| 1 years |
| Manja Bouman | M | - |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | - |
| Erik Lagendijk | M | 64 |
University of Amsterdam
| 3 years |
| Andida Bouma | F | - |
University of Amsterdam
| 4 years |
| Henk ten Hove | M | 72 |
University of Amsterdam
| 1 years |
| Henk A.T. Chin-Sue | M | 71 |
University of Amsterdam
| 3 years |
| Pieter Kodde | M | - |
University of Amsterdam
| 4 years |
| Annemieke J. M. Roobeek | M | 65 |
University of Amsterdam
| 1 years |
| Ada M. Kruisbeek | M | - |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | 9 years |
| René de la Fonteijne | M | - |
University of Amsterdam
| 10 years |
| Christiaan Marie Rutten | M | - |
University of Amsterdam
| 1 years |
| Edward H. Broekhuizen | M | - |
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | 12 years |
| Wim van der Stelt | M | 64 |
University of Amsterdam
| 4 years |
| Eric J. Fischer | M | 78 |
University of Amsterdam
| 3 years |
| Robert Bolier | M | 62 |
University of Amsterdam
| 3 years |
| Gijsbert Groenewegen | M | 66 |
University of Amsterdam
| 3 years |
| Fred Burcksen | M | - |
University of Amsterdam
| 4 years |
| Dolf Starreveld | M | - |
University of Amsterdam
| 6 years |
| Theo Nijssen | M | - |
University of Amsterdam
| 1 years |
| Stephan Lindeman | M | 62 |
University of Amsterdam
| 6 years |
| Jan Dunning | M | 64 |
University of Amsterdam
| 4 years |
| Carla M. C. Mahieu | F | 64 |
University of Amsterdam
| 4 years |
| Johan Lont | M | - |
University of Amsterdam
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Netherlands | 58 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Frank Baas
- Personal Network
